Loading data for GALD.SW — first visit, this takes a few seconds.

Galderma Group AG (GALD.SW)

Swiss: GALD.SW · 实时价格 · USD

167.10

-0.80 (-0.48%)

收盘价： Sep 07, 2026, 3:31 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

暂无数据

买价	166.6
市值	36.9B
营收（TTM）	5.92B
净利润（TTM）	863M
	-0.11
	2.97
	53.32
	29.22
市净率（TTM）	5.55
市销率（TTM）	6.23
财报日期	Mar 4, 2027

卖价	0
成交量	406,037
20日均量	414,465
开盘价	166.65
前收盘价	167.90
日内区间	163.95 - 167.90
52周区间	130.20 - 188.25
分析师	n/a
目标价	n/a
分红	$0.35 (0.22%)
除息日	Apr 24, 2026

关于 GALD.SW

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix...

板块 Healthcare

上市日期 Mar 21, 2024

员工人数 7,676

交易所 Swiss

股票代码 GALD.SW

官网 https://www.galderma.com

公司完整简介

财务表现

2025年，Galderma的营收为5.24B，较上一年的4.44B增长18.04%。净利润为613M，增长165.37%。

财务数据以CHF计财务报表

财报意外

Galderma 已于 Invalid Date 发布季度财报：

营收为 n/a 低于预期 $0, ， NaN% 同比增长.
每股收益为低于预期 , ， NaN% 同比增长.

下次财报发布时间

Galderma Group AG 的下次财报预计于 Mar 4, 2027, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

1月前 · Investing.com

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth f...

1月前 · GuruFocus.com

Galderma Group AG (GDERF) Half Year 2026 Earnings Call Highlights: Record Sales and Strategic ...

Galderma Group AG (GDERF) reports robust sales growth and strategic advancements, while navigating regulatory and market challenges.

2月前 · The Wall Street Journal

Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S.

Shares dropped after the skincare group failed to secure approval for its latest antiwrinkle treatment, a potential rival to AbbVie’s Botox.

2月前 · Investing.com

Galderma falls after FDA issues second setback for Botox rival

Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment Relabotulinumto...

2月前 · Zacks

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

第 1 页，共 2 页

Galderma Group AG (GALD.SW)